Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Making Waves: LSU's WAVCIS Increases Modeling Capabilities
LSU"s WAVCIS, or Wave-Current-Surge Information System for Coastal Louisiana, has a few new tricks up its sleeve in preparation for the 2009 hurricane season.
generic viagra online
Link Between Gene And Increasingly Common Type Of Blood Cancer
California and Arizona researchers have identified a gene variant that carries nearly twice the risk of developing an increasingly common type of blood cancer, according to a study published online by the science journal Nature Genetics.
plastic surgery before after
News of the day
What Is Heart Failure? What Causes Heart Failure?
Even though it may sound like it, heart failure does not necessarily mean that the heart has failed. Heart failure is a serious condition in which the heart is not pumping blood around the body efficiently. The patient"s left side, right side, or even both sides of the body can be affected. Symptoms will depend on which side is affected and how severe the heart failure is - symptoms can be severe.
Oncology

Positive Preclinical Data On 2 Product Candidates At ENDO 09 Presented By Versartis

Versartis, Inc., an emerging company developing novel biologics with enhanced properties for patients with metabolic diseases, presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) for treatment of growth hormone deficiency and for VRS-826 (IL-1ra-rPEG) for treatment of type 1 and type 2 diabetes, at the Endocrine Society"s Annual Meeting in Washington, DC. Versartis, through a unique licensing agreement with Amunix, Inc., uses the Amunix proprietary recombinant PEGylation (rPEG) technology to extend the half-life of established biologics. The preclinical Versartis compounds have the potential for significantly less frequent dosing and fewer side effects than those products currently on the market or in development. "New half-life extension data presented for the first time confirmed our expectation that dosing can be extended from weekly to monthly for our product candidates," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "Our preclinical data show that VRS-317 demonstrated in vivo potency equal to daily hGH, and sustained plasma levels and pharmacodynamic responses in monkeys without toxicity. Potential benefits of VRS-317 include its stability at room temperature in a liquid formulation and the ability to dose monthly with a small gauge needle, thus increasing patient safety and convenience. VRS-317 may become "best in class" hGH therapy when our preclinical studies are confirmed in human clinical trials." "Treatment of auto-inflammation in diabetes with IL-1ra has been demonstrated to increase beta-cell responsiveness in human clinical trials," Dr. Cleland continued. "Our new approach with VRS-826 will provide a less frequently administered treatment that should have comparable safety to IL-1ra, which binds both IL-1b and IL-1a. The results from preclinical studies of VRS-317 and VRS-826 were presented in poster sessions." An Extended Half-Life Human Growth Hormone Construct for Weekly Administration hGH-rPEG Poster Board Number P1-720 Wednesday, June 10, 2009 1:30 - 3:30 pm A Long Half-Life Interleukin-1-Receptor Antagonist for the Treatment of Type 2 Diabetes Mellitus IL-1ra-rPEG Poster Board Number P1-466 Wednesday, June 10,2009 1:30 - 3:30 pm Debra Bannister Versartis, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009